Pluristem Therapeutics Inc (PSTI)

[Auto1]

Maybe INSIDER INFORMATION?!?!?!?!

If indeed this has NOT been published publicly as a corporate 'strategy' or change in focus of 'resources' "in active development" from a previous direction, this would be a 'material disclosure' and a breach of fiduciary responsibility to shareholders. IMO

This deserves a deep-dive to ensure it is NOT the case.[color=red][/color]

PLX-11
Wednesday, 10/03/18 09:31:11 AM
Re: None
0
Post # of 16338

Response from Karine Kleinhaus:

"Hello,

Thank you for reaching out.

We actually have an ongoing phase 1 trial in incomplete recovery following hematopoietic cell transplantation, so the orphan drug designation is for an indication in active development in this case.

We do have the orphan designations you listed, but are prioritizing critical limb ischemia (ongoing phase 3 trial), muscle regeneration (phase 3 trial), acute radiation syndrome (completed phase-2-equivalent trial), and the phase 1 noted above. The platform technology can make multiple PLX products each of which can work in several indications, but as a company we have to focus our resources on a specific strategy. Thank you.

Kind regards,
Karine"




EichKing
Wednesday, 10/03/18 10:19:31 AM
Re: zzaatt post# 16326
0
Post # of 16338

Funny.....We've never heard them state such a thing....or anything regarding those "black hole" projects....must be TOP SECRET.

LMAO